Volume 18, Number 11—November 2012
Pulmonary Streptomyces Infection in Patient with Sarcoidosis, France, 2012
To the Editor: Streptomyces spp. are aerobic, gram-positive bacteria of the order Actinomycetales, known for their ability to produce antimicrobial molecules such as streptomycin. Streptomyces spp., usually saprophytic to humans, can cause local cutaneous fistulized nodules known as actinomycetoma or mycetoma. Severe invasive infections have seldom been reported, but most cases reported have occurred in immunocompromised patients (1–5). We report a case of invasive pulmonary infection caused by a Streptomyces sp. in a splenectomized patient with sarcoidosis.
In 2003, multiorgan sarcoidosis was diagnosed in a man, 57 years of age; the disease involved lungs, skin, joints, and lymph nodes. Corticosteroids were initially given but quickly discontinued because of a severe psychiatric reaction. In 2007, a splenectomy was performed on this patient to remove an intestinal obstruction caused by a severely enlarged spleen, identified as a specific localization of sarcoidosis.
In April 2008, the patient was admitted to the internal medicine unit of Saint-André Hospital in Bordeaux, France with fever (38.9°C/102°F), progressive asthenia, anorexia, weight loss, productive cough, and New York Heart Association grade III dyspnea. Bilateral basal crackles could be heard in the lungs; physical examination findings were otherwise within normal limits. Biological tests showed inflammatory syndrome with elevated C-reactive protein (74 mg/L, reference value <5 mg/L) without any other consequential abnormality. Gamma globulin levels were normal. A chest radiograph showed bilateral interstitial infiltrate. A computed tomography scan of the chest confirmed an interstitial micronodular infiltrate with thickening of the peribronchovascular interstitium, associated with paratracheal and left anterior mediastinal supracentimetric lymph nodes.
To determine whether this infiltrate was linked to sarcoidosis, tuberculosis, or another opportunistic infection, bronchoscopy and bronchoalveolar lavage (BAL) were performed and showed multiple submucous nodules of the left superior bronchus. Biopsy samples contained epithelioid granulomas and a nonspecific, amorphous eosinophilic material without focal necrosis, but no bacteria, by using periodic acid–Schiff, Ziehl–Neelsen, and auramine-rhodamine stains. BAL culture isolated a Streptomyces sp. (2 × 105 CFU/mL) but no other pathogens.
Treatment with intravenous imipenem (2 g/day for 14 days) and amikacin (1 g/day for 3 days) was initiated. After antimicrobial susceptibility tests, the treatment was changed to oral rifampin (1.2 g/day) and ciprofloxacin (1.5 g/day) for 6 months. After 3 days of treatment, clinical signs and symptoms resolved; a thoracic computed tomography scan performed 6 months later showed complete regression of pulmonary infiltrates. Bronchoscopy at that time showed no nodules, and BAL culture showed no pathogens.
Streptomyces spp. are widespread environmental bacteria that rarely cause severe invasive infections. During our literature search, we found 21 cases of invasive Streptomyces infections, including 8 pulmonary infections. A contributing factor was found for all cases: immunosuppression linked to HIV infection (1), antineoplastic chemotherapy (2), Crohn disease (3), use of oral (4) or inhaled corticosteroids (5), and presence of foreign material such as a central venous catheter (6) or a prosthetic aortic valve (7).
Specific features of pulmonary Streptomyces infection are summarized in the Technical Appendix Table [PDF - 86 KB - 3 pages]. Death related to such an infection is mostly dependent on the underlying disease associated with Streptomyces infection. Deaths have not been linked to Streptomyces infections described in the literature when Streptomyces sensibility testing was performed and treatment length recommendations were followed.
To understand how the patient was infected with a Streptomyces sp., we explored 2 possibilities. First, sarcoidosis induces immune deficiency (8). This phenomenon is clinically well known as anergy to tuberculin or other immunogenic haptens after subcutaneous injections. Expansion of regulatory T lymphocytes (8) and attenuated myeloid dendritic cell functions (9) decrease cellular immunity efficiency and increase infectious episodes in affected patients. Second, splenectomy can increase susceptibility to infection, such as bloodstream infections with encapsulated bacteria or opportunistic infections with Campylobacter jejuni, Pneumocystis jiroveci, or Babesia spp. The lung infection with Streptomyces in the patient described was not acquired through the bloodstream, but through direct airway contact. However, we could not exclude other immune mechanisms not related to blood, such as dysregulation or lack of some lymphocyte populations.
A pathologic feature of pulmonary infections with Streptomyces spp. is the presence of granulomas sometimes associated with focal necrosis. This feature makes differentiating infection with these species from that of tuberculosis difficult. Bacterial culture is often used to confirm the diagnosis. Histologic differences between the 2 entities are not well defined because of the rarity of invasive Streptomyces infections. In our observation of this patient, histologic examination revealed granulomas potentially linked to sarcoidosis and a nonspecific, amorphous eosinophilic material that was not caseous necrosis. Both lesions could have also resulted from the Streptomyces infection. For further identification, Dunne et al. added the presence of sulfur granules to the specific histological description of Streptomyces infection (1).
An overall literature review for results of in vitro testing for Streptomyces spp. identified a common susceptibility to aminoglycosides, macrolides, imipenem, or trimethoprim/sulfamethoxazole. This finding suggests that the first-line treatment against invasive Streptomyces infections should begin with imipenem and aminoglycosides for at least 6 weeks (Technical Appendix Table [PDF - 86 KB - 3 pages]). Quinolones have an immunomodulatory effect that might be therapeutic in patients with disease-induced immunosuppression such as sarcoidosis or after splenectomy (10). In conclusion, invasive Streptomyces infection of the lungs should be included in differential diagnoses of interstitial pneumonia in immunocompromised patients.
- Dunne EF, Burman W, Wilson M. Streptomyces pneumonia in a patient with human immunodeficiency virus infection: case report and review of the literature on invasive Streptomyces infections. Clin Infect Dis. 1998;27:93–6.
- Moss WJ, Sager JA, Dick JD, Ruff A. Streptomyces bikiniensis bacteremia. Emerg Infect Dis. 2003;9:273–4.
- Ekkelenkamp MB, de Jong W, Hustinx W, Thijsen S. Streptomyces thermovulgaris bacteremia in Crohn’s disease patient. Emerg Infect Dis. 2004;10:1883–5.
- Kapadia M, Rolston KVI, Xiang Han XY. Invasive Streptomyces infections: six cases and literature review. Am J Clin Pathol. 2007;127:619–24.
- Kofteridis DP, Maraki S, Scoulica E, Tsioutis C, Maltezakis G, Gikas A. Streptomyces pneumonia in an immunocompetent patient: a case report and literature review. Diagn Microbiol Infect Dis. 2007;59:459–62.
- Carey J, Motyl M, Perlman DC. Catheter-related bacteremia due to Streptomyces in a patient receiving holistic infusions. Emerg Infect Dis. 2001;7:1043–5.
- Mossad SB, Tomford JW, Stewart R, Ratliff NB, Hall GS. Case report of Streptomyces endocarditis of a prosthetic aortic valve. J Clin Microbiol. 1995;33:3335–7.
- Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65.
- Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol. 2008;181:746–55.
- Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3:359–71.
Suggested citation for this article: Riviere E, Neau D, Roux X, Lippa N, Roger-Schmeltz J, Mercie P, et al. Pulmonary Streptomyces infection in patient with sarcoidosis, France, 2012 [letter]. Emerg Infect Dis [Internet]. 2012 Nov [date cited]. http://dx.doi.org/10.3201/eid1811.120797
Comments to the Authors
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: October 16, 2012
- Page last updated: October 16, 2012
- Page last reviewed: October 16, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)